ArticleOncology letters2017
Expression of Beclin 1 and Bcl-2 in pancreatic neoplasms and its effect on pancreatic ductal adenocarcinoma prognosis.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Mechanistic insights and therapeutic strategies for targeting autophagy in pancreatic ductal adenocarcinoma.Discover oncology · 2025Review
- STIM1/SOX2 proteins are co-expressed in the tumor and microenvironmental stromal cells of pancreatic ductal adenocarcinoma and ampullary carcinoma.World journal of surgical oncology · 2024Article
- An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer.International journal of molecular sciences · 2023Article
- Mechanistic target of rapamycin (mTOR) regulates self-sustained quiescence, tumor indolence, and late clinical metastasis in a Beclin-1-dependent manner.Cell cycle (Georgetown, Tex.) · 2023Article
- Article
- Cell death in pancreatic cancer: from pathogenesis to therapy.Nature reviews. Gastroenterology & hepatology · 2021Review
- NF-κB and Pancreatic Cancer; Chapter and Verse.Cancers · 2021Review
- Review
- Autophagy as a therapeutic target in pancreatic cancer.British journal of cancer · 2021Review
- Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.BMC cancer · 2020Article
- Beclin-1 expression is associated with prognosis in a Bcl-2-dependent manner in non-small cell lung cancer.Oncology letters · 2020Article
- The Roles of Beclin 1 Expression in Gastric Cancer: A Marker for Carcinogenesis, Aggressive Behaviors and Favorable Prognosis, and a Target of Gene Therapy.Frontiers in oncology · 2020Article
- HisCoM-PAGE: Hierarchical Structural Component Models for Pathway Analysis of Gene Expression Data.Genes · 2019Article
- The autophagy-related genes Beclin1 and LC3 in the prognosis of pancreatic cancer.International journal of clinical and experimental pathology · 2019Article
- Pancreatic panniculitis and solid pseudopapillary tumor of the pancreas: A case report.World journal of clinical cases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of Beclin 1 and B-cell lymphoma-2 (Bcl-2) has been identified in a variety of human tumors; however, little information is available for pancreatic neoplasms. The present study analyzed the expression of Beclin 1 and Bcl-2 in pancreatic ductal adenocarcinoma (PDAC) and solid pseudopapillary neoplasm (SPN) of the pancreas, and evaluated their prognostic significance for PDAC. The present study included 117 PDAC, 43 SPN and 32 chronic pancreatitis (CP) cases. Levels of Beclin 1 and Bcl-2 expression were evaluated semiquantitatively by immunohistochemistry, and their correlation with the survival of patients with PDAC was determined. Beclin 1 was upregulated in 74 (63.2%) PDAC, 26 (60.5%) SPN, and 14 (43.8%) CP cases. Bcl-2 was upregulated in 38 (32.5%) PDAC, 11 (25.6%) SPN and 24 (75.0%) CP cases. High Beclin 1 and low Bcl-2 expression was significantly correlated with poor differentiation and distant metastasis in PDAC, and associated with the presence of nuclear pleomorphism in SPN and with advanced Tumor-Node-Metastasis stage in PDAC. Beclin 1 and Bcl-2 levels were inversely correlated in PDAC, whereas they were positively correlated in SPN. Low Beclin 1 and high Bcl-2 expression was associated with improved disease-free survival and overall survival (OS). However, the association of Beclin 1 with survival was not significant in the Cox analysis, whereas Bcl-2 expression was significantly correlated with OS in the multivariate analysis. In conclusion, Beclin 1 upregulation exacerbated the progression and aggressiveness of pancreatic neoplasms, and Bcl-2 downregulated expression was an independently poor prognostic factor for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.